These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 9333041

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 23. HIV-1 protease inhibitors. A review for clinicians.
    Deeks SG, Smith M, Holodniy M, Kahn JO.
    JAMA; 1997 Jan 08; 277(2):145-53. PubMed ID: 8990341
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes.
    Brandmann M, Tulpule K, Schmidt MM, Dringen R.
    J Neurochem; 2012 Jan 08; 120(1):78-92. PubMed ID: 22017299
    [Abstract] [Full Text] [Related]

  • 26. Nelfinavir. A review of its therapeutic efficacy in HIV infection.
    Jarvis B, Faulds D.
    Drugs; 1998 Jul 08; 56(1):147-67. PubMed ID: 9664204
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
    Shibata N, Matsumura Y, Okamoto H, Kawaguchi Y, Ohtani A, Yoshikawa Y, Takada K.
    J Pharm Pharmacol; 2000 Oct 08; 52(10):1239-46. PubMed ID: 11092568
    [Abstract] [Full Text] [Related]

  • 28. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.
    Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Shetty B, Webber S.
    Antimicrob Agents Chemother; 2001 Apr 08; 45(4):1086-93. PubMed ID: 11257019
    [Abstract] [Full Text] [Related]

  • 29. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM, Winters MA, Lawrence J, Merigan TC.
    AIDS; 1999 Feb 25; 13(3):359-65. PubMed ID: 10199226
    [Abstract] [Full Text] [Related]

  • 30. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
    Shiraki N, Hamada A, Yasuda K, Fujii J, Arimori K, Nakano M.
    Biol Pharm Bull; 2000 Dec 25; 23(12):1528-31. PubMed ID: 11145192
    [Abstract] [Full Text] [Related]

  • 31. Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection.
    Yogev R, Lee S, Wiznia A, Nachman S, Stanley K, Pelton S, Mofenson L, Fiscus S, Jimenez E, Rathore MH, Smith ME, Song LY, McIntosh K, Pediatrics AIDS Clinical Trials Group 338 Study Team.
    Pediatr Infect Dis J; 2002 Feb 25; 21(2):119-25. PubMed ID: 11840078
    [Abstract] [Full Text] [Related]

  • 32. New antiretrovirals and new combinations.
    Havlir DV, Lange JM.
    AIDS; 1998 Feb 25; 12 Suppl A():S165-74. PubMed ID: 9632999
    [Abstract] [Full Text] [Related]

  • 33. Protease inhibitors and prevention of cross resistance.
    Levin J.
    AIDS Treat News; 1995 Oct 06; (no 232):1-3. PubMed ID: 11362875
    [Abstract] [Full Text] [Related]

  • 34. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.
    Patick AK, Duran M, Cao Y, Shugarts D, Keller MR, Mazabel E, Knowles M, Chapman S, Kuritzkes DR, Markowitz M.
    Antimicrob Agents Chemother; 1998 Oct 06; 42(10):2637-44. PubMed ID: 9756769
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.
    Huang F, Allen L, Huang DB, Moy F, Vinisko R, Nguyen T, Rowland L, MacGregor TR, Castles MA, Robinson P.
    J Clin Pharm Ther; 2012 Feb 06; 37(1):81-8. PubMed ID: 21128991
    [Abstract] [Full Text] [Related]

  • 37. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
    Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME, Bell D, Wood K, Sommadossi JP, Pettinelli C.
    AIDS; 1999 Apr 16; 13(6):685-94. PubMed ID: 10397563
    [Abstract] [Full Text] [Related]

  • 38. Vitamin D attenuates nucleoside reverse transcriptase inhibitor induced human skeletal muscle mitochondria DNA depletion.
    Campbell GR, Pallack ZT, Spector SA.
    AIDS; 2013 Jun 01; 27(9):1397-401. PubMed ID: 23435299
    [Abstract] [Full Text] [Related]

  • 39. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function.
    Piccinini M, Rinaudo MT, Anselmino A, Buccinnà B, Ramondetti C, Dematteis A, Ricotti E, Palmisano L, Mostert M, Tovo PA.
    Antivir Ther; 2005 Jun 01; 10(2):215-23. PubMed ID: 15865215
    [Abstract] [Full Text] [Related]

  • 40. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL, Dronda F, Hertogs K, Sabido R, Antela A, Martí-Belda P, Dehertogh P, Moreno S, NELSANE Study.
    AIDS Res Hum Retroviruses; 2001 Jan 20; 17(2):93-8. PubMed ID: 11177388
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.